BioCentury
ARTICLE | Clinical News

PEG-IFN lambda: Phase IIb data

April 14, 2014 7:00 AM UTC

Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: PEG-IFN lambda (peginterferon lambda) ( PEG-rIL-29) Business: Infectious Molecular target: Interleukin-29 (IL-29) (IFNL1) Description: Pe...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article